U.S. markets close in 2 hours 13 minutes

Vyant Bio, Inc. (VYNT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5319-0.0182 (-3.31%)
As of 01:33PM EDT. Market open.

Vyant Bio, Inc.

2 Executive Campus
2370 State Route 70 West Suite 310
Cherry Hill, NJ 08002
United States
201 479 1357

Full Time Employees34

Key Executives

NameTitlePayExercisedYear Born
Mr. John A. Roberts M.B.A., MBAPres, CEO & Director597.69kN/A1959
Mr. Yung-Ping Yeh M.B.A., M.S., P.M.P.Co-Founder & Director351.45kN/A1976
Mr. Andrew D.C. LaFrence CPA, CPAChief Financial Officer355.34kN/A1963
Dr. Robert Thomas Fremeau Jr., Ph.D.Chief Scientific OfficerN/AN/A1955
Dr. Robert J. Petcavich Ph.D.Chief Science Advisor & DirectorN/AN/A1954
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Vyant Bio, Inc., a biotechnology company, discovers drugs for complex neurodevelopmental and neurodegenerative disorders. The company's central nervous system (CNS) drug discovery platform combines human-derived organoid models of brain disease, scaled biology, and machine learning. It focuses on identifying repurposed and novel small molecule clinical candidates for rare CNS genetic disorders including Rett Syndrome (Rett), CDKL5 deficiency disorders (CDD,) and familial Parkinson's disease (PD). Vyant Bio, Inc. has a collaboration agreement to discover drugs for the treatment of Parkinson's Disease. The company is based in Cherry Hill, New Jersey.

Corporate Governance

Vyant Bio, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.